Objective To systematically review the efficacy of routine western medicine（ RWM） plus Chinese oral patent medicines for major adverse cardiovascular and cerebrovascular events（ MACCE） during 6 months or longer after percutaneous coronary intervention（ PCI）. Methods Electronic databases

such as EMBase

Medline

Cochrane Library

CNKI

CBM

and other 11 relevant databases

were searched for randomized control trials that compared oral administration of Chinese patent drugs plus RWM with the same RWM（ or plus placebo） in preventing MACCE during 6 months or longer after PCI. The quality of retrieved literature was assessed by methods from Cochrane Handbook. Valid data were extracted and analyzed by meta-analysis using Rev Man5. 3 and STATA12. 0 software. Results A total of 29 trials（ 4684 patients） met the inclusion criteria and were analyzed. Meta-analysis showed that oral administration of Chinese patent drugs plus RWM could significantly reduce the number of primary endpoint（ RR = 0. 44

95% CI: 0. 32

0. 62

P

<

0. 00001）

cardiac mortality（ RR = 0. 34

95% CI: 0. 15

0

. 74

P = 0. 007）

acute myocardial infarction（ RR = 0. 37

95% CI: 0. 24

0. 58

P

<

0. 0001）

repeat revascularization（ RR = 0. 43

95% CI: 0. 31

0. 58

P

<

0. 00001）

stroke（ RR = 0. 50

95% CI: 0. 29

0. 87

P =0. 01）

readmission for CHD（ RR = 0. 59

95% CI: 0. 46

0. 75

P

<

0. 0001）

heart failure（ RR = 0. 30

95%CI: 0. 15

0. 58

P = 0. 0003）. Conclusions Oral administration of Chinese patent medicines may help prevent long-term MACCE after PCI. Caution should be exercised in drawing a definitive conclusion due to the poor methodological quality.